Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)

Ultragenyx Pharmaceutical Inc. has announced that the first patients have been dosed in its Phase 3 clinical trials evaluating setrusumab for the treatment of Osteogenesis Imperfecta (OI). The Phase 3 portion of the Orbit study is enrolling approximately 195 pediatric and young adult patients, while the newly initiated Cosmic study is enrolling approximately 65 younger pediatric patients. Setrus..